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Abstract: The genomes of polyomaviruses are characterized by their tripartite organization with
an early region, a late region and a noncoding control region (NCCR). The early region encodes
proteins involved in replication and transcription of the viral genome, while expression of the late
region generates the capsid proteins. Transcription regulatory sequences for expression of the early
and late genes, as well as the origin of replication are encompassed in the NCCR. Cell tropism of
polyomaviruses not only depends on the appropriate receptors on the host cell, but cell-specific
expression of the viral genes is also governed by the NCCR. Thus far, 15 polyomaviruses have
been isolated from humans, though it remains to be established whether all of them are genuine
human polyomaviruses (HPyVs). The sequences of the NCCR of these HPyVs show high genetic
variability and have been best studied in the human polyomaviruses BK and JC. Rearranged NCCRs
in BKPyV and JCPyV, the first HPyVs to be discovered approximately 30 years ago, have been
associated with the pathogenic properties of these viruses in nephropathy and progressive multifocal
leukoencephalopathy, respectively. Since 2007, thirteen novel PyVs have been isolated from humans:
KIPyV, WUPyV, MCPyV, HPyV6, HPyV7, TSPyV, HPyV9, HPyV10, STLPyV, HPyV12, NJPyV, LIPyV
and QPyV. This review describes all NCCR variants of the new HPyVs that have been reported in the
literature and discusses the possible consequences of NCCR diversity in terms of promoter strength,
putative transcription factor binding sites and possible association with diseases.
Keywords: disease; Merkel cell carcinoma; mutation; NCCR; novel human polyomaviruses;
transcription factor binding sites
1. Introduction: Human Polyomaviruses
Polyomaviruses (PyVs) are non-enveloped viruses that are typically 40–45 nm in diameter, and
that possess a double-stranded circular genome of around 5000 base-pairs. Birds and mammals,
including humans, are natural hosts for PyVs [1,2]. Recently, PyVs have also been isolated from
fish [3,4]. So far, 15 different polyomaviruses have been isolated from human samples. The first
human polyomaviruses, BKPyV and JCPyV, were identified in 1971 [5,6]. In 2007, two new human
polyomaviruses (Karolinska Institute PyV (KIPyV) [7] and Washington University PyV (WUPyV) [8]
were detected, and in the following years, Merkel cell PyV (MCPyV) [9], HPyV6 [10], HPyV7 [10],
Trichodisplasia spinulosa PyV (TSPyV) [11], HPyV9 [12], HPyV10 [13], Saint Louis PyV (STLPyV) [14],
HPyV12 [15], New Jersey PyV (NJPyV) [16], Lyon IARC PyV (LIPyV) [17], and Quebec PyV [18] have
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been described. Their original source of isolation and association with human diseases is summarized
in Table 1.
Table 1. The novel human polyomaviruses, their original source of isolation and their association with
human diseases.
Virus Original Source Associated Disease Reference
KIPyV Nasopharyngeal aspirate None [7]
WUPyV Bronchoavelar lavage None [8]
MCPyV Merkel cell carcinoma None [9]
HPyV6 Healthy skin Pruritic skin eruption inimmunocompromised patients [10]
HPyV7 Healthy skin Pruritic skin eruption inimmunocompromised patients [10]
TSPyV Trichodysplasia spinulosa spicules Trichodysplasia spinulosa [11]
HPyV9 Serum from renal transplant recipient None [12]
HPyV10 Condyloma specimens from a patientwith WHIM * syndrome None [13]
STLPyV Stool sample from a healthy15-month-old child None [14]
HPyV12 Liver sample from patient withmalignant disease None [15]
NJPyV Muscle biopsy from a pancreatictransplant patient None [16]
LIPyV Skin swab None [17]
QPyV Stool sample from 85-year oldhospital patient None [18]
* warts, hypogammaglobulinemia, infections, and myelokathexis.
Whether all of these are genuine human polyomaviruses (HPyVs) remains to be determined.
BKPyV, JCPyV, KIPyV, WUPyV, MCPyV, HPyV6, HPyV, TSPyV, HPyV9, HPyV10, STLPyV, HPyV12,
and NJPyV are classified as human polyomaviruses by the International Committee of Taxonomy
of Viruses [19,20], LIPyV has only been very recently described, while LIPyV DNA was originally
detected in human skin [17]. LIPyV seroreactivity in healthy individuals is ~5% in healthy individuals
and much lower than the seroprevalence of the other HPyVs, which is between 50–100% [21].
Accordingly, LIPyV DNA was not detected or present in <2% of examined skin, eyebrow hair, gargle
samples and tonsil samples [17,22,23]. Moreover, LIPyV DNA was frequently detected in the feces
of cats [24], suggesting that it may be a feline PyV rather than a HPyV. QPyV DNA was detected in
the feces of one patient [18], and the seroprevalence of this PyV has not been examined. Despite its
original identification in human liver, gastro-intestinal tract and colon tissue and a VP1 seropositivity
(respectively LT seropositivity) between ~20–90% (respectively 30–40%) in healthy adults or malignant
and non-malignant gastro-intestinal tract patients [15,25], HPyV12 DNA could not be detected in
numerous human samples from different sources [22,26–30]. Moreover, the group of Feltkamp reported
that HPyV12 seroprevalence is only around 5% [21,31]. A nearly identical HPyV12 variant was isolated
from shrew, suggesting that HPyV12 may be transmitted from shrew to humans, or that human
HPyV12 positive samples were contaminated [32].
2. The Polyomavirus Genome: The Noncoding Control Region
Functionally, the PyV genome is tripartite consisting of the early region, the late region, and the
noncoding control region (NCCR) (Figure 1A). The early region codes for regulatory proteins involved
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in replication and transcription of the viral genome. The major early proteins are large T-antigen (LT)
and small t-antigen (sT). The late region codes for the structural proteins VP1, VP2 and VP3 that form
the capsid. VP1 is the major capsid protein, while VP2 and VP3 are the minor capsid proteins [1,2].
However, not all PyVs express VP3 [33]. Interspersed between the early and late region are sequences
that do not code for viral proteins, and is referred to as the NCCR.
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Figure 1. Genomic organization of the human polyomaviruses (HPyVs) genome and the structure of 
the noncoding control region (NCCR). (A) The circular dsDNA genome consists of the early and late 
regions that encode regulatory and structural proteins, respectively. Interspersed is the NCCR. (B) 
Schematic presentation of the NCCR of the novel HPyVs. The NCCR is the region between the start 
codon of Large T antigen (LT) and Small T antigen (sT) and the start codon of VP2. The AT-rich region 
(AT), repeated sequences (black dots), and LT binding motifs (upward pointing triangle = 5′-GRGGC-
3′; downward pointing triangle = 5′-GCCYC-3′) are shown. (C) Phylogenetic tree bases on NCCR 
sequences of the different HPyVs. This is a neighbor-joining tree without distance corrections using 
Clustal Omega multiple sequence alignment [34]. 
Studies with simian virus 40 (SV40 or Macaca mulatta polyomavirus 1) and murine 
polyomaviruses have been pivotal in unveiling the functions of this region. The SV40 NCCR contains 
the origin of replication (ori), which consists of GRGGC motifs to which LT binds and is flanked by 
an AT-rich sequence and an easily denaturated imperfect palindrome [35,36]. Binding of LT to these 
motifs is also involved in regulation of viral transcription [37,38]. The NCCR also contains promoter 
and enhancer elements that control early and late transcription [39,40]. SV40 directly isolated from 
its natural host, rhesus monkey, has a NCCR that consists of an AT-rich region, triple GC-rich 21 
base-pairs (bp) repeats, and a single 72 bp element. The 21 bp repeats contain the LT binding motif 
(GRGGC; [41,42]). This NCCR organization is known as the archetype. SV40 adapted to grow in cell 
culture has a duplication of this 72 bp element, with this type of NCCR referred to as prototype 
[43,44]. SV40 isolated from human tumors usually contain a single 72 bp repeat [43]. Rearrangements 
in the SV40 NCCR affect viral transcription and replication, as well as oncogenic properties of the 
virus [45,46]. The Mouse polyomavirus (Mus musculus polyomavirus 1; MPyV) NCCR encompasses 
the ori consisting of an AT-tract and a GC-rich (LT binding motifs) inverted repeat, and the 
transcription regulatory domains A (or α) and B (or β), C and D [47–50]. Alterations in the MPyV 
Figure 1. Genomic organization of the human polyomaviruses (HPyVs) genome and the structure
of the noncoding control region (NCCR). (A) The circular dsDNA genome consists of the early and
late regions that encode regulatory and structural proteins, respectively. Interspersed is the NCCR.
(B) Schematic presentation of the NCCR of the novel HPyVs. The NCCR is the region between the
start codon of Large T antigen (LT) and Small T antigen (sT) and the start codon of VP2. The AT-rich
region (AT), repeated sequences (black dots), and LT binding motifs (upward pointing triangle =
5′-GRGGC-3′; downward pointing triangle = 5′-GCCYC-3′) are sho n. (C) Phylogenetic tree bases on
NCCR sequences of the different HPyVs. This is a neighbor-joining tree without distance corrections
using Clustal Omega multiple sequence alignment [34].
Studies with simian virus 40 (SV40 or Macaca mulatta polyomavirus 1) and murine polyomaviruses
have been pivotal in unveiling the functions of this region. The SV40 NCCR contains the origin of
replication (ori), which co sists of GRGGC motifs to wh ch LT binds and is flanked by an AT-rich
sequence and an easily denaturated imperfec palindrome [35,36]. Binding of LT to these motifs is also
involved n regulation of viral transcription [37,38]. The NCCR also contains promoter and enhanc r
elements that co trol arly and e transcription [39,40]. SV40 directly isolated fr m its natural hos ,
rhesus monkey, has a NCCR that consists of an AT-rich region, triple GC-rich 21 base-pairs (bp) r peats,
and a single 72 bp el ment. Th 21 bp repeats contain the LT binding motif (GRGGC; [41,42]). T is
NCCR organization is known as the archetyp . SV40 adapted to grow in cell culture has a duplication
of this 72 bp element, with this type of NCCR referred to as p oto [43,44]. SV40 is lated from
human tumors usually c tain a ingle 72 bp r peat [43]. Rearrangements in the SV40 NCCR affect
viral transcription an eplication, as well as oncogenic properties of the virus 5,46]. The Mouse
polyomavirus (Mus mus ulus polyomavirus 1; MPyV) NCCR encomp sses the ori consisting of an
AT-tract and a GC-rich (LT binding motif ) inverted repeat, and the transcription regulatory domains A
(or α) and B (or β), C and D [47–50]. Alterations in the MPyV NCCR have an effect on viral replication
in cell ulture and in the host, the host range, a in vitro transformation [51–55].
The NCCR of the HPyVs varies between 267 bp (JCPyV CY-strain; accession number AB038249) to
645 bp (WUPyV prototype; accession number NC_009539) (see Figure S1 for the NCCR sequences of the
novel HPyV), and similar to the NCCR of SV40 and MPyV, the NCCR of HPyVs also contain the origin
of replication, LT binding motifs, and AT-rich region (Figure 1B). This region of the genome displays
little or no sequence identity between the different HPyV species (Figure S2). A neighbor-joining tree
without distance corrections shows which NCCRs are most closely related (Figure 1C).
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The diversification based on the presence of a certain NCCR rearranged structure contributed to
determining HPyVs strains as “archetype” or prototype”. The importance of the NCCR rearrangements
during HPyVs infection became obvious when different strains of JCPyV were examined. The
archetype JCPyV NCCR strain (CY) is divided into six boxes named A (36 bp), B (23 bp), C (55 bp),
D (66 bp), E (18 bp), and F (69 bp) and contains the origin of replication (ORI), the promoter and the
enhancer elements [56]. The NCCR harbored transcription factor binding sites such as the nuclear
transcription factor-1 (NF1), a JCPyV cell-specific regulator of promoter and enhancer activity [57,58],
the activating protein 1 (AP1), involved in JCPyV early gene expression [57,59], and the specificity
protein-1 (SP1) able to regulate JCPyV transcription [57,60]. The archetype NCCR is considered the
transmissible form of the virus among the population, and could be released into the urine of healthy
individuals due to periodic and subclinical reactivation in the kidney [61,62]. In contrast, in the
context of immunosuppression or during immunomodulatory therapy or in AIDS patients, JCPyV
can reactivate from latency to cause a fatal pathology of the central nervous system (CNS), known as
progressive multifocal leukoencephalopathy (PML) [61]. JCPyV variants carrying rearranged NCCR
were usually isolated from PML patients. The prototype Mad-1 strain is the most studied variant of
JCPyV and is characterized by 98-bp tandem repeats in the NCCR late proximal region (arranged
as ORI-A-C-E-A-C-E-F), and is able to increase viral gene expression in human glial cells, thereby
indicating that it is involved in controlling cell gene expression [63–65]. The enhancer repeats found
in the Mad-1 strain are lacking in the archetype JCPyV strains isolated from the urine of healthy
individuals [64]. Additional NCCR rearrangements are implicated in the development of the JCPyV
pathogenic strains. In fact, in a significant proportion of JCPyV archetype isolates, short deletions or
duplications were observed, corroborating that this region is highly unstable [66,67]. Therefore, it is
possible to assume that subsequent archetypal NCRR rearrangements could determine the onset of
PML strains, such as Mad-1 [68].
Based on the occurrence in the NCRR of transcriptional enhancer repeat elements, BKPyV
isolates can also be identified as archetype and prototype strains. The archetype BKPyV WW strain,
characterized by five blocks named O (35 bp), which includes the origin of replication and a TATA-box,
P (68 bp), Q (39 bp), R (63 bp), and S (63 bp), containing TATA-like elements and the regulatory
regions for early and late genes expression, is considered the infectious strain, shed in the urine of
immunocompetent individuals [69–71]. Approximately 30 transcription factor binding sites are in
silico predicted: SP1 has been the most extensively studied [72–74], although the additional role played
by other transcription factors such as NF1, ETS1, NFκB, the glucocorticoid and progesterone receptors,
and CREB were evidenced in several studies [73,75–77].
Similarly to JCPyV, the plausible instability of the archetype BKPyV NCRR could contribute to
the development of the prototype strains, which is able to cause polyomavirus-associated nephropathy
in kidney transplant recipients and hemorrhagic cystitis in hematopoietic stem cell transplant
recipients [78–81]. The Dunlop strain, the most salient prototype strain, was isolated from a kidney
transplant recipient with ureteral stenosis [82]. This strain displays three 68-bp tandem repeat within
the NCRR (O-P-P-P-S arrangement) with respect to the archetype strain, carrying a single 68-bp motif.
This strain showed less enhancer activity than the prototype strain, thus confirming the significance of
the triplicated motifs on transcriptional regulation, and on viral infectious activity [83]. In fact, BKPyV
strains isolated from kidney transplant recipients with rearranged NCRR showed higher viral gene
expression and viral loads with more extensive pathogenicity [84].
Additional NCCR structures have been described for both viruses [85–88]. In particular, the
presence of a common pattern of JCPyV NCCR rearrangement, such as the D-box deletion, can
be considered a hallmark needed for the initial NCCR rearrangements critical co-factor for the
development of PML in immunosuppressed individuals [88,89]. Besides the triplication of the P region,
rearrangements of BKPyV NCCR involve the adjacent O and Q blocks. Differently, the S block is always
retained, hence highlighting the importance of these nucleotide sequences [70]. NCCR mutations were
also observed during in vitro JCPyV and BKPyV cultivation, confirming that NCRR variants could
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arise after prolonged propagation of the viruses in cells [71,85,90,91]. The mechanisms by which both
viruses determine relevant human diseases are not established, but it is accepted that the regulation
of gene expression in HPyVs plays a role in determining the viral tropism, and in the promotion of
pathogenesis progression [92].
Little is known about the genetic diversity of the NCCRs from the novel HPyVs and the biological
relevance in terms of viral transcription, replication, and possible pathogenic properties. In this review,
we provide an overview of the mutations in the NCCR, which is defined as the sequence between the
start codon of the LT/sT gene and the start codon of the VP2 gene, of the novel HPyVs and their known
effect on promoter activity. We discuss how NCCR rearrangements may affect the binding of putative
transcription factors, and whether specific NCCR configurations are associated with disease.
3. KI and WU NCCR Variants
KIPyV has been mostly isolated from oral and respiratory specimens from (pediatric) patients with
respiratory diseases that suffer from other viral and bacterial infections (reviewed in [93]). Whether
KIPyV is a genuine respiratory pathogen or an opportunistic co-infector has not been established [93,94].
Seventy-two full-length NCCR sequences have been deposited in GenBank so far (Table S1). They
contain the LT binding motifs, an AT-rich stretch and repeated sequences (Figure 1B and Table 2).
Table 2. Repeat sequences in the noncoding regions of the novel human polyomaviruses.
HPyV Sequence Position Length Remarks
KIPyV CGTGAAGCCAACTTCCTG-GGCCGTG-AGCCAGCTTCCTGCGGC
251–271;











HPyV6 No repeats - -
HPyV7 No repeats - - -
TSPyV GAAATGAA 34–41; 42–49 7 DR
HPyV9 CTGTGGTAT 275–283; 284–292 9 DR
HPyV10 GCTATTGTTGGCAA 168–181;182–195 14 DR






GTTCC is part of
larger repeat
DR separated by 1
nucleotide
NJPyV No repeats - - -
LIPyV No repeats - - -
QPyV No repeats - - -
* DR = direct repeat. Repeat sequences were identified using the programs Tandem Repeat finder program [95] and
the repeat sequence finding tool from Novoprolabs (novoprolabs.com/tools/repeat-sequence-finder).
Most KIPyV NCCR sequences are obtained from nasopharyngeal swabs or aspirates, but also
from blood form healthy blood donors [96] and from feces from a child with acute gastroenteritis [97].
The NCCR sequence of the Stockholm 60 isolate (Genbank accession number NC_009238; [7]; Figure
S1) may represent the archetype NCCR because it is the most common sequence reported, and has been
isolated from different biological samples in different parts of the world. Stockholm 60 KIPyV was
originally isolated from respiratory tract specimens from a child. We found that 21 out of 48 isolates
from nasopharyngeal aspirates of patients with respiratory symptoms or infections and 23 out of 38
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isolates from healthy blood donors have the Stockholm 60 NCCR [96]. As described by us and others,
NCCRs of other isolates, contain only minor point mutations scattered throughout the entire NCCR
(Figure 2 and Table 3). Exceptions are the isolates Brisbane 001, Brisbane 005 and CU-255, whose
NCCRs have the 10 bp AGGCGCTGCG insertion, and are clinical isolates obtained from respiratory
tract (Table S1).
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i trol region ( CCR). The numbering of the NC R is from early to late, with nucleotide 1
being the most proximal to he ATG star codon f the early genes and the most distal nucleotide, just
upstream of the start codon of the VP2 gene. The number of times a peculiar mutation is found i the
different variants is given as fr quency (with n the number of times the mutation was described/tot l
NCCR variant sequences available). Putative Large T antig n (LT) bindin motifs 5′-GRGGC-3′ (→)
or 5′- CYC-3′ (←) are shown. The table summarizes the utations, their location in the NCCR
and their frequency. For details, see Table S1. Putative transcription factor bindi g sites are shown in
Supplementary Table S2.
The KIPyV NCCR contains putative binding sites for several transcription factors (Table 4 and
Table S2). The effect of this 10 bp AGGCGCTGCG insertion on KIPyV promoter activity or replication
is not known, but the sequence contains a putative binding site for transcription factor AP4 [98].
AP4 is ubiquitously expressed, and can both activate and repress transcription [99,100]. Its effect on
KIPyV NCCR has not been investigated. The point mutations remove or create putative binding
sites for several transcription factors, including nuclear receptors, STAT proteins, HOXD, and POU
the general transcription factors TBP and TFIID (see Table 3 in [101] for a detailed overview). We
examined the effect of NCCR polymorphism in isolates from blood and nasopharyngeal samples on
early and late promoter activity in HEK 293 cells [96]. These cells had previously been shown to
give highest promoter activity of 10 different cell lines tested [102]. Eighteen isolates with a single
nucleotide substitution were tested and revealed significant differences in early and late promoter
activities for some of the isolates. One variant (NPA7d) had a mutation that destroyed a putative
c-Myb binding motif compared to Stockholm 60 NCCR. Ectopic expression of c-Myb stimulated the
early and late promoter activities of both Stockholm 60 and NPA7d, but there was no significant
difference in c-Myb induced activation of the promoters [96]. Some of the mutations are located in
putative LT binding sites and may therefore have an effect on promoter activity or/and viral DNA
replication. It remains to be determined whether the NCCR may have an effect on the pathogenic
properties of KIPyV because Stockholm 60 and Stockholm 60-like NCCRs have also been isolated from
blood and respiratory specimens from healthy individuals, with no direct association between KIPyV
and diseases having been established. Larger KIPyV NCCR rearrangements as seen for BKPyV and
JCPyV NCCRs seem to be rare.
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Table 3. Frequency of mutations in the noncoding control region of Karolinska Institute polyomavirus.
Mutation Frequency * Mutation Frequency Mutation Frequency
C8A 1 A132insAGGCGCTGCG 3 T248A 1
T24A 1 T149C/A 4 G290A 1
T28C 3 T154C 1 G291A 1
T30A 1 A162T 1 T294C 1
A33G 1 A163C 1 T297C 2
C36T 1 A166G 1 T300C 1
T41C 1 T180C/A 10 A305G 1
C46T 1 A181C 1 C306A 10
A57G 1 T183G/A 10 T336C 1
T60C 1 G188A 2 ∆G352 1
C77T 1 T189C 1 A371G 1
T78C 1 A196G 1 A381T 1
C85T 1 C208T 1 T411C 1
A99G 1 T217A 1 A415G 1
A101T 1 G224A 1 T416C 1
T111C 2 A231G 1 C418T 1
G116A 1 A234G 1 C444T 1
T121A 1 T235A 1 C455T 1
G125A 2 T247C 1 G484A 6
* n/72.
A total of 185 partial or complete WUPyV NCCR sequences are available in the GenBank (Table
S1). All strains have a NCCR of 645 bp, except variant J1, which has an insertion of one A at position 277
(Table S1), and contains an AT-rich stretch, GRGGC pentamers and repeated sequences of, respectively,
10 and 16 bp (Figure 1B and Table 2). Polymorphisms are predominantly in the NCCR part proximal
to the early region (Figure 3 and Table 5). The most common point mutations are G54A and T59G.
Both mutations are often present simultaneously. The substitution C52G is also common, but is always
found in combination with the G54A mutation. The variants GD-WU709 and WU/Wuerzburg01/07
have C52T rather than C52G, whereas 12 variants have the triple mutation C52G/G54A/T59G. These
three nucleotides are part of a sequence that is flanked, respectively, by 4 and 5 T residues; the triple
substitution removes the putative binding site for transcription factor c-MYB, and creates motifs for
TATA/TBP and retinoic acid receptor-related orphan receptor α [98]. The mutations A94G and C105G
are also always simultaneously present, with the double mutations generating a remote sequence
similarity with the binding motif of transcription factor AP1, though this does not seem to affect
the binding of other putative factors (Table S2; [98]). Other common mutations include A284C and
C285A, which are also found together except for the WU/Wuerzberg03/07 variant, which lacks the
A284C substitution. A284/C285 are part of a putative site for RUNX1 (AML1; [98]), a transcription
factor involved in hematopoiesis [103]. While G295A is found in 9 NCCR sequences, one strain
(CQ6029/China_CQ/2014) had a G295C replacement. The CU_CHONBURI3 isolate from a patient with
respiratory diseases had several unique point mutations. Overall, no typical mutations in specific
specimens were detected, nor was an apparent correlation with a genotype and geographic regions.
To the best of our knowledge, the effect of mutations on the WUPyV promoter activity has not been
studied, nor have the consequences of viral replication been addressed. Whether mutations had an
effect on putative transcription factor binding sites is also unknown, but because most mutations are
single or few point mutations, they may not destroy or create novel binding sites.
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Table 4. Number of putative transcription factor binding sites in the noncoding control region of the novel human polyomaviruses. Prediction based on TFBIND
tool [98].
Transcription
Factor KIPyV WUPyV MCPyV HPyV6 HPyV7 TSPyV HPyV9 HPyV10 STLPyV HPyV12 NJPyV LIPyV QPyV
AML1 6 3 3 6 4 6 6 3 4 2 7 4 3
ARNT 2 0 0 3 2 4 2 2 2 5 4 2 2
AP1 8 9 10 6 8 14 8 7 10 4 5 5 5
AP2 12 13 6 7 6 6 5 6 5 5 7 3 0
AP4 8 12 5 0 6 6 5 5 9 4 9 3 3
ATF/CREB 7 11 6 4 8 14 5 6 10 2 5 3 8
CAAT 7 7 3 5 5 7 8 9 4 3 6 4 5
C/EBP 7 9 8 9 9 12 13 9 4 7 7 11 0
CDP 2 2 0 1 1 1 2 4 3 3 2 1 1
E2F 9 10 4 4 5 14 9 6 8 6 7 5 2
E47 7 8 1 2 5 3 5 4 4 2 6 2 2
ELK1 10 8 9 5 4 12 8 8 3 6 8 6 5
EVI1 3 6 4 3 4 9 7 3 4 4 5 5 5
GATA-1 7 12 9 8 6 16 15 9 6 6 7 10 8
GATA-2 6 8 5 3 5 13 8 6 4 8 3 5 7
GATA-3 5 0 2 1 5 8 6 1 0 0 1 4 3
GR 2 0 0 1 2 3 0 2 1 3 0 1 3
HNF3 3 4 2 2 1 4 1 3 4 1 2 0 2
IRF 5 3 6 4 4 2 3 4 0 2 4 3 3
MYB 6 5 6 7 0 4 6 6 3 7 2 7 1
MYC/MAX 5 7 1 2 2 6 3 2 2 3 4 1 1
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Table 4. Cont.
Transcription
Factor KIPyV WUPyV MCPyV HPyV6 HPyV7 TSPyV HPyV9 HPyV10 STLPyV HPyV12 NJPyV LIPyV QPyV
MYOD 9 9 3 3 5 7 8 6 8 8 5 6 2
NF1 5 5 3 1 1 4 1 6 4 3 4 2 1
NFκB 2 3 5 2 1 5 7 5 0 1 1 1 1
NHLH1 2 2 2 1 1 1 0 0 1 0 1 1 0
OCT1 9 17 11 8 7 16 16 6 8 8 13 9 9
p53 7 8 5 4 3 8 9 5 1 11 10 5 3
PAX2 3 1 0 3 1 4 2 1 2 5 5 1 4
PAX5 7 4 5 2 3 3 8 1 5 2 3 1 3
PAX6 1 2 0 1 0 0 2 0 1 1 2 0 2
SOX5 3 7 4 2 4 8 2 5 7 2 5 4 4
RORα 7 4 3 4 6 5 4 1 2 6 2 0 3
SP1 12 12 14 6 8 13 10 9 7 11 8 11 11
SREBP 3 1 1 1 2 1 1 3 5 0 2 1 3
SRF 3 5 1 4 2 7 5 3 0 3 3 1 5
STAT 3 6 2 2 3 7 2 3 3 2 5 1 0
T3R 6 6 1 3 1 1 3 2 3 2 3 0 4
TBP 5 10 5 5 5 5 5 4 4 6 2 3 5
TST-1 3 5 4 2 0 4 2 2 1 0 1 2 1
USF 12 12 3 6 7 13 7 8 5 4 8 2 7
YY1 3 3 4 3 6 6 5 1 1 3 2 2 3
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Table 5. Frequency of mutations in the noncoding control region of Washington
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Mutation Frequency * utation Frequency Mutation Frequency
C28T 1 C245A 1 G316A 1
C52G 33 C249A 1 G319A 1
G54A 114 C251A 18 G326A 2
T76C 1 G252T 1 T346G 17
A94G 15 G253A 1 A347G 1
G104C 1 C254A 5 C358G 20
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Viruses 2020, 12, 1406 12 of 30
4. MCPyV NCCR Variants
NCCR rearrangements are described as a pivotal event in the onset of HPyVs-related pathology,
as demonstrated for JCPyV and BKPyV, in which NCCRs not only control gene expression, but also
serve as the main determinants in viral replication, containing the origin of DNA replication and
transcription factor binding sites [104,105]. MCPyV is a major causative agent of the skin cancer Merkel
cell carcinoma [9], but whether the NCCR can influence the outcome of the infection remains elusive.
More than 100 partial or complete NCCR sequences are available from MCC and non-MCC tissue
(Table S1). Mutations have been described throughout the entire NCCR, but especially in the late
promoter part region (Figure 4 and Table 6). Nucleotides 360–425 of the MCPyV NCCR contain putative
binding sites for transcription factors AP1, AP2, C/EBPα and β, EVI1, NFκB, c-Myb, p53, SOX5, TST-1,
and SP1 (Table 4; [98]), although their binding has not been proven so far. Some of the mutations
affect putative LT binding motifs, and may therefore interfere with transcription and replication of the
viral DNA. Indeed, studies by the group of Chang and Moore showed that mutations in nucleotides
G143, C145A, A173 and C176 abolished the replication of MCC isolates MCV339 and MCV350 in the
presence of full-length LT [106,107]. The NCCR from MCC isolates FraMerk22 and FraMerk24 both
contain the mutations G143T and C176T, whereas MCC isolate MKT-23 has the mutations G143A,
C145G, and A173A, with MKT-32 carrying the transversion C146G. Since all these isolates are derived
from MCC, they are replication deficient due to the expression of truncated LT and integration. None
of the mutations identified by the work of the Chang-Moore group that abrogate MCPyV replication
have been reported in non-MCC PyV isolates (see Table S1).
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Table 6. Frequency of mutations in the noncoding control region of Merkel cell polyomavirus.
Mutation Frequency * Mutation Frequency Mutation Frequency
T5G 1 G188A 2 T371insCAAT 1
C6G 1 T210C 1 C372ins(T/A)(C)AAC 19
C13T 1 G212insA 2 T373A/insCAAC/∆T373 6
C26A 1 ∆A213/A213insA 5 T374C/insAA 2
G32C 3 ∆A214 1 T379insT/∆T379 3
A38G 1 A234T 3 ∆381–387 3
G40A 1 A251C 1 C383insAA 5
C51T 1 C272T 1 ∆C392 3
T52C 1 ∆G274 1 C393T 1
T86C 1 ∆G300 1 ∆G396 1
T94C 1 G301A 1 ∆A397 1
T102A 1 ∆A304 1 C400insT 2
∆105–112 2 G309A 1 ∆T401 2
T108G 1 G311A 1 ∆T402 1
T123C 1 ∆316–323 2 ∆T407 3
G143T/A 3 ∆A320 1 T408A/∆T408 14
C145G 1 ∆322–327 1 ∆C409 1
T146C 1 A325T 2 T412A 1
G152T 2 A326G/ ∆A326 3 ∆T423–425 1
C158T 1 T349C 1 ∆A433 1
∆T161 2 ∆G352 40 A435G 17
C170T 2 A361G 1 C448A 1
A173G 1 G363A 22 T449C/∆T449 7
C176T 2 ∆T368 3 ∆T456/∆456–460 18
T178C 1 T369ins(T)(C)AAC(T)(C)/∆T369 14 ∆T457 17
* n/113.
Whether a MCPyV variant with a particular NCCR architecture is associated with specific patient
groups is not known. MCPyV with different NCCRs have been characterized in Merkel cell carcinoma
samples (see Table S1), while for other diseases only a single sample of a particular individual was
examined. Few studies have examined a larger cohort and/or different clinical samples from the
same patient. Hashida, et. al. evaluated the genetic variability of MCPyV NCCR in skin swab
specimens of healthy individuals with distinct ethnicities and geographic origins, identifying two
major subtypes of MCPyV NCCR, subtypes I and II, with the presence or absence of a 25 bp tandem
repeat (TGTCCTCCTCCCTTTGTAAGAGAAA) in the late promoter region. Based on the occurrences
of two deletions (T368 and T369), and the 5 bp TCAAC insertion (compared to the consensus strain
R17b), MCPyV strains were further assigned to five genotypes [108]. Delbue et.al. performed MCPyV
NCCR molecular characterization on cerebrospinal fluid samples collected from patients affected by
neurological disorders. The results obtained showed the presence of the MCPyV NCCR IIc strain,
according to Hashida’s NCCR classification [109]. Prezioso, et al., studying the MCPyV NCCR from
urine, plasma and rectal swabs recovered from immunosuppressed population, observed, in plasma
and rectal swabs, as well as the occurrence of the MCPyV NCCR IIa-2 strain, which contains the 5
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bp insertion and represents the predominant strain among white persons of European descent [110].
The deletion of nucleotide G352 is unique for the MCPyV isolates in plasma, urine and rectal swab
specimens from HIV-1 patients, and has not been described in MCPyV isolates from other patient
groups. In addition to the NCCR genotypes circulating within a HIV-1-positive population in the same
study, Prezioso et al. evaluated the MCPyV NCCR alterations focusing on putative binding sites of
cellular transcription factors, in order to verify whether mutations and/or rearrangements could fall in
some binding sites [110]. The analysis of distal NCCR sequences (nucleotides 302–464) and the analysis
of the relative putative binding site, revealed a high degree of homology with R17b strain in urine
samples, whereas transitions, transversions, and single or double deletions were observed in plasma
and rectal swabs (Table S1). Differently from JCPyV and BKPyV, in which the early proximal side of
NCCR is highly conserved and the late proximal side undergoes rearrangements [111], insertions and
deletions occurred in both the early and late proximal side of the MCPyV NCCR. More specifically,
representative TCAAT and AAC insertions (nucleotide positions 5210–5211) were observed in both
plasma and rectal swabs. Analysis of the putative binding site showed that the MCC350 NCCR
sequence contains putative NF1, NFκB, TST-1, OCT1, AP-1, and TATA sites, already described within
the NCCRs of other HPyVs [98,112]. In several strains obtained from MCPyV-positive plasma and rectal
swabs samples, deletions, insertions, or single base substitutions fell within these putative binding
sites, thus making predictable that some of these changes would not allow the identification of putative
binding motifs, such as SP1 and/or p53, already described in the NCCR of other HPyVs [112]. Further
studies are warranted in order to define the importance of these NCCR binding sites and to understand
how their changes (mutations, insertions, or deletions) may influence in vivo MCPyV pathogenicity. In
contrast to NCCR analysis conducted on rectal swabs from an HIV-1-positive population, which were
characterized by the onset of transitions, transversions, and single or double deletions [110], MCPyV
NCCR in stool samples from patients with hematological disorders exhibited a high degree of sequence
stability, thereby suggesting that sequence rearrangements occurred rarely in the gastrointestinal
anatomical site [113]. To date, although it is well documented that MCPyV DNA has been detected in
the upper and lower respiratory tract specimens of children and adults and in immunocompetent and
immunocompromised patients [114–118] and that the detection of MCPyV DNA was also observed in
cystic fibrosis patient respiratory secretions [119,120], the respiratory NCCR structure organization has
not yet been investigated.
The relative early and late promoter strength of seven MCPyV NCCR variants was compared
in human dermal fibroblasts, and in the non-classical MCPyV-positive MCC cell line MCC13 [121].
All variants that had mutations compared to the consensus strain R17b (GenBank accession number
HM011556) had a 10–50% lower basal early and late activity in both cell lines. However, the I strain
described by Hashida et al. ([108]) had an approximately 30% higher early and late promoter activity
and the early promoter of isolate MKL1, a MCC isolate [122], was approximately 40% stronger in
the fibroblasts. The promoter activity of other variants has not been compared, nor has the effect of
mutations on the viral life cycle and transforming potential of this oncovirus been examined.
5. HPyV 6 and HPyV7 NCCR Variants
Although HPyV6 and HPyV7 DNA is commonly present in the normal skin of healthy
persons [10,123], HPyV6 and HPyV7 are associated with rash and pruritic skin eruption [124–128],
HPyV7 DNA was found in 19/35 cholangiocarcinomas [129], while HPyV6 DNA has been
detected in a few cases of keratoacanthomas, basal cell carcinomas, squamous cell carcinomas
and trichoblastomas [130,131]. HPyV6 DNA was detected in 1/234 cerebrospinal fluid samples and
1/1016 serum samples of healthy blood donors [109,132]. HPyV6 DNA prevalence was much higher
in tonsil brushing samples from immunocompetent children and adults than HPyV7 DNA (113/689
versus 6/689). HPyV6 and HPyV7 DNA prevalence and copy number were significantly higher in skin
swabs collected from lesional and non-lesional skins of 86 Japanese patients with inflammatory skin
diseases and mycosis fungoides compared with specimens from 149 healthy control individuals [133].
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HPyV6 and HPyV7 were detected in 1/55 skin specimens from cutaneous T-cell lymphoma patients [29].
Despite the presence of HPyV6 and HPyV7 DNA in samples of various disorders, it remains to be
established whether these viruses play a direct role in causing such skin conditions.
Seventeen HPyV6 NCCR sequences are deposited in GenBank. Four of them are sequences
obtained from HPyV6 DNA amplified in sewage (H6-cg-A2.f, B159.4, U43.1 and U43.3), six are
from healthy skin (606b, 607a, 607b, 609a, 614a, and 627a), two are from bile samples (Bile-72 and
Bile-81), and two are combined nose and throat samples from kidney transplant patients (QLD-49Br
and QLD-61Br). One sample was obtained from pruritic skin lesion (UTSW6.1), one from a lymph
node from a patient with an angiolymphoid hyperplasia with Kimura disease (LN1), and one from a
nasopharyngeal aspirate of a child with respiratory tract infections (BJ376) (see Table S1 for details and
references). Identical HPyV6 NCCRs were found in healthy skin, along with bile from patients with
malignant biliary obstruction, combined nose and throat specimens from kidney transplant patients
and a nasopharyngeal sample of a child with respiratory infection (Table S1). Two clinical samples
(UTSW6.1 from pruritic skin and LN1 from the lymph node of a patient with Kimura disease) and the
DNA amplified from sewage water had mutations compared to the reference strain. The mutation
spectrum is shown in Figure 5 and Table 7. The UTSW6 isolate had a deletion of nucleotides 183–193
(CAAAGGTCAAA), a mutation of nucleotides 223–229 (except 228), and insertions of GGC and of
TGGGCAGGGCCATTT distal of these point mutations. The 11 bp deletion removes binding motifs for
AP1 and CREB, while the 15 bp insertion adds a putative SP1 and p53 binding site. Other putative
binding sites are shown in Table 4 and Table S2. The point mutations affect an AT-rich region but no
putative binding motifs are predicted in this sequence [98], which may affect viral replication, as this
region is part of the predicted ori [134]. Based on the limited available HPyV6 NCCR sequences, no
specific HPyV6 NCCR is associated with disease. The effect of mutations in the NCCR on the promoter
activity and viral life cycle has not been tested.
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The numbering of the NCCR is from early to late with nucleotide 1 being the most proximal to the
ATG start codon of the early genes and the most distal nucleotide, just upstream of the start codon
of the VP2 gene. The number of times a peculiar mutation is found in the different variants is given
as frequency (with n the number of times the mutation was described/total NCCR variant sequences
available). Putative Large T antigen (LT) binding motifs 5′-GRGGC-3′ (→) or 5′-GCCYC-3′ (←) are
shown. The table summarizes the mutations, their location in the NCCR, and their frequency. For
details see Table S1. Putative transcription factor binding sites are shown in Supplementary Table S2.
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Table 7. Frequency of mutations in the noncoding control region of HPyV6.
Mutation Frequency * Mutation Frequency Mutation Frequency
T17C 1 ∆183–193 1 T231insG 1
C18T 1 A223C 1 C232insG 1
G22A 2 A224T 1 C234insTGGGCAGGGCATTT 1
C65T 1 A225G 1 C243T 3
C78G 2 T228C 1 T287C 3
A116G 2 T229A/insGGC 1 A356G 1
* n/17.
Sequences of 15 different HPyV7 NCCR isolates are available in GenBank (variants 707a, 707b,
713a, 713b, 715b, 727a, CRC01, PITT1, PITT2, UTSW7.1, PLA1, PLA2, MUQ, URI, and BIO). Six are
from healthy skin specimens, while nine are clinical samples from patients, including skin lesions from
lung or renal transplant patients with rash and pruritus, and skin lesions from patients with pruritic
and dyskeratotic dermatoses (Table S1 and references therein). The length of these NCCRs varies from
371 bp (PITT2 isolate) to 399 bp (PITT1 isolate). DNA of these two variants was isolated from the skin
of lung transplant patients with a rash [124]. Five isolates from the same patient had an NCCR of
381 bp (BIO, MUQ, PLA1, PLA2, URI), five had a 383 bp NCCR (707a, 707b, 715b, 727a, UTSW7.1),
two had a 385 bp NCCR (713a and 713b), and one had a NCCR of 387 bp (CRC01). No repeated
sequences are present (Table 2). The mutations in the different HPyV7 variants are concentrated in
the central part of the NCCR (Figure 6 and Table 8). The consensus is the nucleotide sequence that
was present in the majority of the 15 available sequences, with the nucleotide numbering based on the
HPyV7 reference strain R713a (GenBank accession number NC_014407=713). Most mutations are point
mutations, whereas PITT1 also contains the insertion ACAGGATATGAT and PITT2 has a deletion
removing nucleotides 150–161 (CTGGGTTACTGG). The insertion contains putative binding sites for
the transcription factors ETS1, GATA1/2/3 and EVI1, whereas the deletion removes possible GATA2
and CDP binding motifs [98]. EVI1, CDP and GATA3 are expressed in the skin, while ETS1, GATA1,
and GATA2 are not or weakly expressed in skin [100]. Putative binding sites for transcription factors
in the HPyV7 NCCR are summarized in Table 4 and Table S2.
Table 8. Frequency of mutations in the noncoding control region of HPyV7.
Mutation Frequency * Mutation Frequency Mutation Frequency
G99A/C 10 G161insTCA 1 ∆T205 10
A100T 1 G162C/insACAGGTATGAT 2 G228T 10
∆T149 1 C164T 5 G230C/R 7
∆C150/∆150–161 2 ∆A180 5 C279G/insTT 6
C158G 5 ∆G181 5 G315T 11
T159(C)(A)/insA 7 G203A 10
G160A 9 C204G/∆C204 11
* n/18.
The early promoter activity of the PITT1 and PITT2 variants was significantly higher than the
activity of the reference strain in the colon adenocarcinoma cell line SW480, whereas a tendency to
lower activity in human embryonal kidney HEK293 cells was observed [112]. The promoter activity
was not examined in skin cells, although these variant were originally isolated from the skin [124].
Colon and kidney cells may not be authentic host cells because no HPyV7 LT expression was detected in
10 normal and 94 malignant colon samples, and in 10 normal and 65 renal cancers [135] and so far there
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are no reports of HPyV7 DNA in these organs. A transversion of A to T in the putative 5′-GAGGC-3′
LT motif was reported (Figure 6), although the effect on viral replication has not been exploited.
Interestingly, the NCCR of the recently isolated QPyV DNA shows >80% identity with the HPyV7
NCCR (Figure S3), while the complete genome is 81% identical with HPyV7 [18].
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G99A/C 10 G161insTCA 1 ΔT205 10 
A100T 1 G162C/insACAGGTATGAT 2 G228T 10 
ΔT149 1 C164T 5 G230C/R 7 
ΔC150/Δ150–161 2 ΔA180 5 C279G/insTT 6 
C158G 5 ΔG181 5 G315T 11 
T159(C)(A)/insA 7 G203A 10   
G160A 9 C204G/ΔC204 11   
* n/18. 
The early promoter activity of the PITT1 and PITT2 variants was significantly higher than the 
activity of the reference strain in the colon adenocarcinoma cell line SW480, whereas a tendency to 
lower activity in human embryonal kidney HEK293 cells was observed [112]. The promoter activity 
was not examined in skin cells, although these variant were originally isolated from the skin [124]. 
Colon and kidney cells may not be authentic host cells because no HPyV7 LT expression was detected 
in 10 normal and 94 malignant colon samples, and in 10 normal and 65 renal cancers [135] and so far 
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GAGGC-3′ LT motif was reported (Figure 6), although the effect on viral replication has not been 
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Figure 6. Mutations and their prevalence in variants of HPyV7 noncoding control region (NCCR).
The numbering of the NC R is from early to late ith nucleotide 1 being the most proximal to the
ATG start codon of the early genes an the ost distal nucleotide, just upstream of the start codon
of t e P2 gene. The number of times a peculiar mutation is found in the different variants is given
as frequency ( ith n the u ber of ti es the utation was described/total N CR variant sequences
av il ble). Putative Large T antigen (LT) binding motifs 5′ - ′ ( ) or 5′-GCCYC-3′ (←) are
shown. The table summarizes the mutati i i t e CR, and their frequency. For
details see Table S1. Putative transcription fact r i r s o n in Su plementary Table S2.
6. TSPyV NCCR Variants
Twenty-four TSPyV NCCR sequences are deposited in the Ge Bank (Table S1). Most samples
are derived from skin spicules, but also a nasopharyngeal aspirate from a heart transplant patient, a
heart from a myocarditis patient, and the CSF and serum of immunosuppressed patients contained
TSPyV DNA. The NCCRs of the non-spicule isolates were identical or quasi identical with isolates
from skin spicules. Most mutations are point mutations (Figure 7 and Table 9), but two skin spicule
isolates (0602 and 1312) had deletions of 54 and 38 bp, respectively [136]. The relative promoter activity
of these NCCR variants has not been examined, nor has the effect of mutations on the viral life cycle
been investigated. The 39 bp deletion removes putative binding sites for AP1, SOX5, HNF3, OCT1,
TATA/TBP, STAT, glucocorticoid receptor, retinoic acid receptor-related orphan receptor α, and CREB,
whereas 54 bp deletion possesses possible binding sites for ARNT, AP1, AP2, AP4, CREB/ATF, CAAT,
E2F, ELK, EVI1, GATA1/2/3, NHLH1, MYB, MYC, MYOD, NFκB, OCT1, PAX5, TST1, and USF [98].
While most of these factors are expressed in the skin, MYOD, PAX5, GATA1, and GATA2 seem to be
absent in the ski [100]. How ver, the binding of these transcription factors and their pos ible role in
regulating TSPyV transcription rem in to be proven. The TSPyV NCCR contains several putativ LT
binding motifs, and mutations in some of th m have bee reported (Figure 7). Whether they have an
effect on viral replication has not been tested.
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Table 9. Frequency of mutations in the noncoding control region of Trichodisplasia
spinulosa polyomavirus.
Mutation Frequency * utatio Frequency * Mutation Frequency *
G84C 6 ∆318 1 C514G 6
C103A 1 A356G 20 G516T 6
C138insA 6 G358T 6 C538Y 1
A173G 6 G359A/G359insA 13 T543insC 6
C210T 1 A422T 1 G546C 6
A224G 1 G428C 13 T552C 6
∆257–295 1 C456G 2 C555G 6
G297A 5 T496G
* n/24.
7. HPyV 9 NCCR Variants
HPyV9 was originally detected in the serum and urine from a renal transplant patient under
immunosuppressive treatment [12]. Shortly after, HPyV9 DNA was isolated from the facial surface of a
Merkel cell carcinoma patient and tentatively named Institute Pasteur polyomavirus (IPPyV) [137]. The
genome of IPPyV only differs by two nucleotides from HPyV9, hence IPPyV is a variant of HPyV9. Yet,
none of these mutations are within the NCCR (Table S1; [137]). The HPyV9 isolate M149 from tonsils
has an identical NCCR sequence as the original HPyV9 isolate (GenBank accession MH844627). An
HPyV9 isolate (UF-1 isolate) from the blood of an AIDS patients displays an eight base-pair deletion, a
13 base-pair insertion and 24 point mutations in its NCCR [138]. These NCCR rearrangements created
putative SP1 binding sites in the late promoter. We compared the basal early and late promoter activity
of the original HPyV9 strain and the UF-1 clinical isolate in the human cell lines BEL7402, C33A,
HEK293, HeLa, SK-N-BE, SW480, and U2OS. We found that the UF-1 early promoter was stronger in
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all cell lines except in U2OS, and the UF-1 late promoter was stronger in all cell lines except in C33A
and HeLa cells [139]. The effect of LT on early and late promoter activity was monitored in BEL7402,
HEK293 and HeLa cells. Whereas the UF-1 late promoter activity was more potently stimulated than
the HPyV9 late promoter by LT in all three cell lines tested, a stronger LT-induced activation of the
UF-1 early promoter compared to the HPyV9 early promoter was only observed in HEK293 cells. The
mutations in the UF-1 NCCR generate two putative SP1 binding sites in the distal part of the late
promoter. Mutating these two SP1 sites did not have an effect on the basal early promoter activity, but
increased basal late promoter 2-fold. Disruption of these SP1 sites had also no effect on LT-induced
early promoter activity, but reduced late promoter activity 7-fold compared to non-mutated late UF-1
promoter activity. Our results showed that the promoter activity of the clinical isolate UF-1 is stronger
and more potently induced by LT compared with the promoter of the original HPyV9 isolate. A later
study confirmed that the UF-1 promoter was stronger than the promoter of the original isolated HPyV9
in HEK293 and the lung carcinoma A549 cells [112]. Whether the rearrangements in the UF-1 NCCR
may affect the life cycle and possible pathogenic properties of the virus remains to be determined.
Additional putative transcription factor binding sites are summarized in Table 4 and Table S2.
8. HPyV10 NCCR Variants
Twenty NCCR sequences are available in GenBank (Table S1), with the length ranging from
to 430 to 442 bp. The original isolates MWPyV (NC_018102) and MA095 (JQ898291), both from
feces [140], are identical, but contain an 11 bp deletion compared to the other variants (Table S1, Figure 8
and Table 10). The NCCRs of isolates ww10, TEDDY-01, QLDMW04 and QLDMW10 are identical,
although they were derived from different specimens from different patients. The ww10 isolate was
detected in a condyloma specimen from a patient with warts, hypogammaglobulinemia, infections, and
myelokathexis (WHIM) syndrome [13], QLDMW04 and 010 are from respiratory samples [141], and
TEDDY_01 is from feces (direct submission to GenBank; accession number KC549591). Point mutations
are dispersed throughout the NCCR for the other isolates. The 11bp deletion (ATTGTTGGCAA)
contains possible binding sites for CDP and SOX5 [98]. CDP is ubiquitously expressed, but SOX5 is
enriched in testis [100]. Other possible transcription factors that may bind the HPyV10 NCCR are
given in Table 4 and Table S2. It is not known whether HPyV10 is associated with a disease, and the
biological consequence of NCCR mutations remains elusive.
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Table 10. Frequency of mutations in the noncoding control region of HPyV10.
Mutation Frequency * Mutation Frequency Mutation Frequency
G21C 1 ∆A180 1 G263A 5
T22C 1 ∆G192 1 A287C 1
A24C 1 ∆A194 1 G311A 1
G28C/∆G28 3 A195G/∆A195 4 G338A 1
G40A 1 G196C 4 G345A 1
C53G 5 A198G/∆A198 6 C354A 2
G57C 1 G201A/∆G201 5 C356G 1
∆C65 1 ∆T203 1 C363G 1
C131G 1 ∆A204 1 G372A 1
T132insG 1 A208G 1 C389G 1
A145G 1 A215T 6 A395C 1
C146T 1 T222C 1 G396T 3
G160A 7 G225A/C 2 A422 1
C166T 5 T256C/∆T256 8 C433A 3
∆171–181 1 A259A 1
* n/20.Viruses 2020, 12, x  20 of 30 
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9. STLPyV NCCR Variants
Sequences of 7 STLPyV NCCRs are available in GenBank (Table S1). These variants were
discovered in feces, respiratory swab or peri-anal warts [14,26,27,142,143]. Point mutations and one
bp deletions have been observed (Figure 9 and Table S1), although the biological implications on
promoter activity and viral replication have not been examined, nor has their possible role in disease
been defined. So far, no variants with mutations in the possible LT binding motifs have been isolated.
Putative binding sites for transcription factors in the STLPyV, NCCR are shown in Table 4 and Table S2.
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and their frequency. For details see Table S1. Putative transcription factor binding sites are shown in
Supplementary Table S2.
10. HPyV12, NJPyV, LIPyV and QPyV Variants
The NCCR sequence of two HPyV12 isolates is known. One of them carries a 26 bp deletion in
the distal part of the late promoter (nucleotides 297–322) (Table S1; [102]). This deletion reduces the
early and late promoter activity in 10 different human cell lines tested, except for the early promoter
activity in BEL7402 and HEK293 cells, in which a significantly higher activity was measured compared
with the early promoter activity of the original HPyV12 isolate [102]. The deletion eliminates putative
c-MYB, CREB and AP4 binding sites, but it is not known whether these transcription factors actually
bind the HPyV12 promoter.
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Only one human and one feline LIPyV isolate have been reported, and they differ by four-point
mutations (Table S1). No NJPyV and QPyV NCCR variants have been described thus far. Putative
binding sites for transcription factors in the HPyV12, NJPyV and LIPyV NCCR are summarized in
Table 4 and Table S2.
11. Conclusions
Similar to BKPyV and JCPyV, novel HPyV isolates with mutations in their NCCR are commonly
detected in human samples. However, for the most recently described PyVs isolated from human
specimens, none or very few isolates have been reported, and large deletions and/or duplication are
lacking. Our knowledge of the effect of mutations in the NCCR on viral promoter activity and viral
replication is incomplete because only a few studies have addressed the effect of NCCR mutations
on the promoter activity, while the impact on viral replication has not been examined. Replication
studies have been hampered by the lack of permissive cell systems for all novel HPyVs, except dermal
fibroblasts which support productive MCPyV infection [144]. The HPyV NCCRs contain a plethora of
binding motifs for host cell proteins, but their binding to the NCCR has not been confirmed. Chromatin
immunoprecipitation assays at the early and late stages of infection may allow for the identification of
transcription factors involved in early and late expression. Another unsolved question for most of the
novel HPyVs is whether they are associated with specific diseases. Apart from MCPyV and its etiologic
role in MCC, TSPyV as the causative agent of trichodysplasia spinulosa [9,145–147], and HPyV6 and
HPyV7 with pruritic skin eruption in immunocompromised patients [124–128], firm evidence for
pathogenic properties of the other novel HPyVs is lacking. So, far no specific MCPyV, HPyV6, HPyV7,
and TSPyV NCCR variants seem to be associated with disease because virus variants with (quasi)
identical NCCRs were also detected in samples from healthy individuals. Studies on different patient
groups are required to unveil possible novel HPyV-associated diseases, as more NCCR sequences from
larger and different patient cohorts are required to establish a possible connection between the genetic
diversity of the NCCR and disease. The biological consequences of NCCR mutations for the viral life
cycle warrants further investigation.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4915/12/12/1406/s1,
Table S1: mutations in the NCCRs of the novel HPyV. Table S2: Putative transcription factor binding sites in the
NCCR of the novel HPyVs. Figure S1: NCCR sequence of the novel HPyVs. Figure S2: alignment of the NCCR
from the novel HPyVs. Figure S3: Alignment of the HPyV7 and QPyV NCCRs.
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IPPyV Institute Pasteur polyomavirus
KIPy Karolinska Institute polyomavirus
LIPyV Lyon IARC polyomavirus
LT Large T antigen
MCC Merkel cell carcinoma
MCPyV Merkel cell polyomavirus
MPyV Mouse polyomavirus
NCCR Non-coding control region
NJPyV New Jersey polyomavirus
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PML Progressive multifocal leukoencephalopathy
QPyV Quebec polyomavirus
sT Small T antigen
STLPyV Saint Louis polyomavirus
TSPyV Trichodisplasia spinulosa polyomavirus
WUPyV Washington University polyomavirus
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